IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Iovance Biotherapeutics raised full-year 2026 revenue guidance from $350–370M to $410–420M (midpoint +$55M, ~15% increase). 2Q26 revenue was ~$99M, 10% above 2Q guidance, with 56% gross margin on cost of sales. The company reported ~$304M cash (as of June 30, 2026) with runway into 2H 2028. Amtagvi (lifileucel) commercial launch is driving 66% YoY growth in 2Q26, with ~100 authorized treatment centers in North America and expansion into multiple global markets. Pipeline includes Phase 3 TILVANCE-301 in frontline melanoma and Phase 2 programs in NSCLC, soft tissue sarcoma, and endometrial cancer.
Why this rating
Material revenue upside and margin expansion show commercial execution and proof of Amtagvi adoption. However, $410M guidance is small vs. $535M market cap; company remains pre-profitability with cash runway pressure by 2H28.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.